Biblio
Acute Graft-versus-Host-Disease other than typical targets: between myths and facts. Biol Blood Marrow Transplant. 2020.
. AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. Eur J Cancer. 2022;181:102-118.
. Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. Bone Marrow Transplant. 2021.
CD19-CAR-T cells are an effective therapy of post-transplant relapse in B- ALL patients: Real-World Data from Germany. Blood Adv. 2023.
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients. Hemasphere. 2023;7(10):e957.
Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study. Bone Marrow Transplant. 2023.
Data-driven grading of acute graft-versus-host disease. Nat Commun. 2023;14(1):7799.
ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party. Front Immunol. 2023;14:1283034.
ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party. Bone Marrow Transplant. 2024.
Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting. Hematology. 2022;27(1):723-732.
. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study. J Immunother Cancer. 2024;12(1).
ERS/EBMT clinical practice guideline on treatment of pulmonary chronic graft--host disease in adults. Eur Respir J. 2024.
GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022.
Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study. Blood Adv. 2022.
Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2023.
Long-Term Survivors After Failure of CAR-T Cell Therapy for Large B-Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A GLA/DRST Analysis. Transplant Cell Ther. 2023.
Management of Patients undergoing CAR-T cell therapy in Germany. Oncol Res Treat. 2024.
Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant. 2018.
Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant. 2018.
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Front Immunol. 2023;14:1252811.
.